Anixa Biosciences is trading 6.1% down at $3.34 today, giving back a portion of its recent rebound as the broader biotech sector faces selling pressure.
- The decline comes despite a pre-market gain, with no fresh company-specific news or catalysts tied directly to the reversal.
- The move appears to be driven by shifting market sentiment and a cooling in risk appetite following a strong tech-led rally.
- Absent new corporate developments, the stock is currently sliding in tandem with broader industry trends.